Kestra Medical Q4 revenue beats estimates on higher market share & WCD expansion
KMTS•Key reported figures
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q4 Revenue | Beat | $28.64 mln | $26.48 mln (7 Analysts) |
| Q4 EPS | -$0.67 | ||
| Q4 Adjusted EBITDA | Miss | -$26.70 mln | -$22.46 mln (6 Analysts) |
| Q4 Gross Profit | $15.68 mln | ||
| Q4 Income from Operations | -$39.34 mln |
FY27 outlook and analyst view
Kestra expects fiscal 2027 revenue of $137 million, up 44% from fiscal 2026.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy".
Wall Street's median 12-month price target for Kestra Medical Technologies Ltd is $30.00, about 21.2% above its July 13 closing price of $24.76.
Margins improve, but adjusted EBITDA loss widens
Gross margin expanded due to volume leverage, a higher mix of in-network patients and execution of planned cost improvement programs.
Q4 adjusted EBITDA loss widened and missed analyst estimates.
Q4 revenue beats as market share and WCD expansion drive growth
Kestra Medical Technologies said fourth-quarter revenue rose 66% year over year, beating analyst expectations.
